Special Issue "Cancer Systems Biology and Natural Products"

A special issue of Processes (ISSN 2227-9717). This special issue belongs to the section "Biological Systems".

Deadline for manuscript submissions: 30 June 2020.

Special Issue Editor

Prof. Dr. Bonglee Kim
E-Mail Website
Guest Editor
Department of Pathology, College of Korean Medicine, Kyung Hee University
Tel. 821090001406
Interests: Oncology; Epigenetics; MiRNA; Natural products; Phytomedicine

Special Issue Information

Dear Colleagues,

Cancer systems biology has emerged because cancer is a complicated disease system involving complex molecular and genetic events. Recent developments of technologies in genomics and proteomics have provided methods and information to researchers with a holistic view of cancer and the local microenvironment, while traditional cancer research only focuses on single mutations or alterations. Natural products include naturally-produced chemical compounds or substances from any living organism. The benefits of natural products have been reported in the form of studies of traditional medicine for the treatment of several human diseases, including Alzheimer’s disease, inflammatory diseases, influenza disease, and cancer. Multi-target drugs based on natural products have been discovered, such as curcumin, resveratrol, etc., and approved by the U.S. Food and Drug Administration. Natural products could be primary sources of cancer drug discovery in terms of cancer systems biology.

We propose a Special Issue on “Cancer Systems Biology and Natural Products” to publish high-quality work focusing on novel and recent advances in natural products in cancer system biology applications, including traditional medicine, biomaterials, etc. The topics of interest include, but are not limited to:

  • Cancer systems biology
  • Cancer microenvironment
  • Natural products for cancer therapy
  • Traditional medicine for cancer therapy

Prof. Dr. Bonglee Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Processes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Please note that for papers submitted after 30 June 2020 an APC of 1500 CHF applies. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer systems biology
  • Cancer microenvironment
  • Natural products
  • Traditional medicine
  • Epigenetics

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessFeature PaperArticle
The Effects of Lung-Moistening Herbal Medicines on Bleomycin-Induced Pulmonary Fibrosis Mouse Model
Processes 2020, 8(1), 102; https://doi.org/10.3390/pr8010102 - 12 Jan 2020
Abstract
In traditional medicine, lung-moistening herbal medicines (LMHM) are regarded as a major option for treating symptoms of pulmonary fibrosis (PF) including dry cough and dyspnea. As PF agents are being applied to the development of lung cancer agents, PF and lung cancer are [...] Read more.
In traditional medicine, lung-moistening herbal medicines (LMHM) are regarded as a major option for treating symptoms of pulmonary fibrosis (PF) including dry cough and dyspnea. As PF agents are being applied to the development of lung cancer agents, PF and lung cancer are reported to have high pathological and pharmacological relationships. This study was proposed to identify candidates for the treatment of PF via investigating the effect of LMHM on PF mouse model. PF was induced by intratracheal instillation of bleomycin. Six water extracts of LMHM such as Farfarae Flos (FAF), Trichosanthis Semen (TRS), Lilii Bulbus (LIB), Adenophorae Radix (ADR), Asteris Radix (ASR), and Scrophulariae Radix (SCR) were prepared and administered (300 mg/kg) orally for 10 days after induction. The changes in body weight, histopathology, and immune cell of bronchoalveolar lavage fluid (BALF) were investigated. Among those, LIB and ADR significantly decreased the deposition of collagen and septal thickness of alveolar and terminal bronchiole. Moreover, SCR, TRS, LIB, and ADR decreased total cells, macrophages, and lymphocytes in BALF. Taken together, ADR and LIB could be the candidates to reduce PF. Further studies on their effects at different doses and analysis of their underlying molecular mechanisms are needed. Full article
(This article belongs to the Special Issue Cancer Systems Biology and Natural Products)
Show Figures

Graphical abstract

Open AccessArticle
Baicalein-Enriched Fraction Extracted from Oroxylum indicum (L.) Benth. ex Kurz Leaves Exerts Antioxidant and Inhibitory Effects Against Glioblastoma Multiforme
Processes 2019, 7(12), 963; https://doi.org/10.3390/pr7120963 - 16 Dec 2019
Abstract
Glioblastoma multiforme (GBM) is the most malignant subtype of primary brain cancer. To date, standard clinical treatment for GBM is limited in effectiveness and could impose additional side effects. Recently, numerous bioactive compounds isolated from natural plants appear to have beneficial anti-cancer properties. [...] Read more.
Glioblastoma multiforme (GBM) is the most malignant subtype of primary brain cancer. To date, standard clinical treatment for GBM is limited in effectiveness and could impose additional side effects. Recently, numerous bioactive compounds isolated from natural plants appear to have beneficial anti-cancer properties. Here, the GBM inhibitory effect of baicalein, a bioactive flavonoid extracted from Oroxylum indicum (L.) Benth. ex Kurz, was evaluated. Firstly, three solvents were used to extract the baicalein. We found that the binary extraction system, using a combination of petroleum ether and methanol (PM), yielded the highest amount of baicalein (15%) compared to the mono extraction system using methanol (13%) or aqueous (0.04%) only. In order to further enhance the baicalein yield in PM crude extract, it was subjected to an enrichment fractionation procedure, which successfully increased the baicalein by nearly two-fold from the initial crude extract (15%) to the enriched fraction 5 (F5) (29%). The enriched F5 not only showed significantly higher (~2.5-fold) antioxidant properties as compared to the crude extract, it was also found to significantly suppress GBM cell proliferation ~2.5-fold better than the crude extract. In conclusion, this study successfully optimized an extraction procedure for increased yield of baicalein metabolite from O. indicum leaves and enhanced its therapeutic potential for GBM treatment. Full article
(This article belongs to the Special Issue Cancer Systems Biology and Natural Products)
Show Figures

Figure 1

Back to TopTop